)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Zhejiang Huahai Pharmaceutical
Zhejiang Huahai Pharmaceutical (600521) investor relations material
Zhejiang Huahai Pharmaceutical Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
9M 2026 revenue rose 15.86% YoY to RMB 7.425bn; attributable net income increased 178.61% to RMB 1.060bn.
Q3 revenue grew 32.75% YoY to RMB 2.512bn; attributable net income was RMB 288.8m, versus a loss in the prior-year quarter.
Financial highlights
9M operating profit was RMB 1.246bn versus RMB 555.2m YoY; total profit rose 134.41% to RMB 1.287bn.
9M adjusted for non-recurring items, attributable net income was RMB 702.0m, up 159.96% YoY; Q3 adjusted income was RMB 275.7m.
9M operating cash flow increased 134.25% to RMB 1.528bn; Q3 operating cash flow rose 52.13% YoY to RMB 430.2m.
Outlook and guidance
R&D priorities remain focused on products with competitive strengths, advancing innovative drugs and high-end complex generics and API projects with more mature development progress.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Zhejiang Huahai Pharmaceutical
- Net profit surged 88% YoY to RMB 770.91 million on strong core growth and one-off gains.600521
Q2 2026 - Revenue and profit fell sharply, but R&D and innovation pipelines advanced amid industry headwinds.600521Q4 2025
- Net profit jumped 35.90% on a one-time gain, but core profit and revenue declined year-over-year.600521Q1 2026
- Revenue and profit fell significantly amid higher R&D costs and market competition.600521Q3 2025
- Revenue and profit declined sharply amid price pressure and higher R&D, but innovation advanced.600521Q2 2025
- Net profit jumped 85.09% in Q3 2024 on robust sales and improved margins.600521Q3 2024
- Net profit surged 31.60% on 19.43% revenue growth, led by new products and global expansion.600521Q2 2024
- Net profit jumped 34.74% on 14.91% revenue growth, with robust R&D and strong cash flow.600521Q4 2024
- Net profit rose 9.81% year-over-year despite a 5.21% revenue decline in Q1 2025.600521Q1 2025
Next Zhejiang Huahai Pharmaceutical earnings date
Q4 202630 Apr, 2027
Zhejiang Huahai Pharmaceutical
Next Zhejiang Huahai Pharmaceutical earnings date
Q4 202630 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)